Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 6175-6181, November 15, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagawa, M.
Right arrow Articles by Cowan, K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagawa, M.
Right arrow Articles by Cowan, K. H.

Reduced Intracellular Drug Accumulation in the Absence of P-Glycoprotein (mdr1) Overexpression in Mitoxantrone-resistant Human MCF-7 Breast Cancer Cells

Masayuki Nakagawa, Erasmus Schneider, Katharine H. Dixon, Julie Horton, Kristin Kelley, Charles Morrow and Kenneth H. Cowan1

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892

A mitoxantrone-resistant human MCF-7 breast cancer subline (MCF/MX) which is approximately 4000-fold resistant to mitoxantrone was isolated by serial passage of the parental wild-type MCF-7 cells (MCF/WT) in stepwise increasing concentrations of drug. MCF/MX cells were also approximately 10-fold cross-resistant to doxorubicin and etoposide but were not cross-resistant to vinblastine. Intracellular accumulation of radiolabeled mitoxantrone was markedly reduced in MCF/MX cells relative to that in the drug-sensitive MCF/WT cells. This decrease in intracellular drug accumulation into MCF/MX cells was associated with enhanced drug efflux, which was reversed when cells were incubated in the presence of sodium azide and 2, 4-dinitrophenol, suggesting an energy-dependent process. Incubation of MCF/MX cells with verapamil did not affect either the accumulation of mitoxantrone or the level of resistance in these cells. Furthermore, RNase protection and Western blot analyses failed to detect the expression of the mdr1 RNA or P-glycoprotein, a drug efflux pump known to be associated with the development of multidrug resistance in vitro. However, a polyclonal antibody directed against a synthetic peptide corresponding to the putative ATP binding domain of P-glycoprotein reacted with two (Mr 42,000 and 85,000) membrane proteins from MCF/MX cells which were not found in MCF/WT. Functional assays and Western blot analysis for topoisomerase II revealed no differences in topoisomerase II activity or protein levels in MCF/MX cells. Thus, resistance in this cell line is apparently associated with enhanced drug efflux involving a pathway distinct from the mdr1-encoded multidrug transporter P-glycoprotein.

1 To whom requests for reprints should be addressed, at Building 10, Room 12N226, National Cancer Institute, Bethesda, MD 20892.

Received 9/ 5/91. Accepted 9/ 9/92.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Kasibhatla, V. Baichwal, S. X. Cai, B. Roth, I. Skvortsova, S. Skvortsov, P. Lukas, N. M. English, N. Sirisoma, J. Drewe, et al.
MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps
Cancer Res., June 15, 2007; 67(12): 5865 - 5871.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman, and A. J. Townsend
Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux
Mol. Pharmacol., April 1, 2006; 69(4): 1499 - 1505.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Nakamura, M. Oka, H. Soda, K. Shiozawa, M. Yoshikawa, A. Itoh, Y. Ikegami, J. Tsurutani, K. Nakatomi, T. Kitazaki, et al.
Gefitinib ("Iressa", ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2-Mediated Drug Resistance
Cancer Res., February 15, 2005; 65(4): 1541 - 1546.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. L. Volk and E. Schneider
Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter
Cancer Res., September 1, 2003; 63(17): 5538 - 5543.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. C. Lockhart, R. G. Tirona, and R. B. Kim
Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy
Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X. Wang, T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto, S.-I. Akiyama, and M. Baba
Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors
Mol. Pharmacol., January 1, 2003; 63(1): 65 - 72.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. L. Volk, K. M. Farley, Y. Wu, F. Li, R. W. Robey, and E. Schneider
Overexpression of Wild-Type Breast Cancer Resistance Protein Mediates Methotrexate Resistance
Cancer Res., September 1, 2002; 62(17): 5035 - 5040.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Kim, H. Turnquist, J. Jackson, M. Sgagias, Y. Yan, M. Gong, M. Dean, J. G. Sharp, and K. Cowan
The Multidrug Resistance Transporter ABCG2 (Breast Cancer Resistance Protein 1) Effluxes Hoechst 33342 and Is Overexpressed in Hematopoietic Stem Cells
Clin. Cancer Res., January 1, 2002; 8(1): 22 - 28.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider
Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux
Cancer Res., July 1, 2000; 60(13): 3514 - 3521.
[Abstract] [Full Text]


Home page
J. Cell Sci.Home page
T Litman, M Brangi, E Hudson, P Fetsch, A Abati, D. Ross, K Miyake, J. Resau, and S. Bates
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
J. Cell Sci., January 6, 2000; 113(11): 2011 - 2021.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
Z.-S. Chen, T. Furukawa, T. Sumizawa, K. Ono, K. Ueda, K. Seto, and S.-I. Akiyama
ATP-Dependent Efflux of CPT-11 and SN-38 by the Multidrug Resistance Protein (MRP) and Its Inhibition by PAK-104P
Mol. Pharmacol., May 1, 1999; 55(5): 921 - 928.
[Abstract] [Full Text]


Home page
JNCI J Natl Cancer InstHome page
D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. C. Cole, and L. A. Doyle
Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines
J Natl Cancer Inst, March 3, 1999; 91(5): 429 - 433.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Hazlehurst, N. E. Foley, M. C. Gleason-Guzman, M. P. Hacker, A. E. Cress, L. W. Greenberger, M. C. De Jong, and W. S. Dalton
Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line
Cancer Res., March 1, 1999; 59(5): 1021 - 1028.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.